Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.

Registrati

Quotazioni in diretta

JANX Janux Therapeutics Inc

48,00

-0,82 (-1,68%)

27 Nov 2024 - Chiuso

Dati in Delay di 15 minuti

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

09/27/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Andrew Hollman Meyer

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Grafico Azioni Janux Therapeutics (NASDAQ:JANX)
Storico
Da Ott 2024 a Nov 2024

Clicca qui per i Grafici di Janux Therapeutics

Grafico Azioni Janux Therapeutics (NASDAQ:JANX)
Storico
Da Nov 2023 a Nov 2024

Clicca qui per i Grafici di Janux Therapeutics

Notizie Janux Therapeutics Inc - JANX

Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies
Lunedì 25 Novembre 2024 (2 giorni fa) • Business Wire

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Giovedì 14 Novembre 2024 (2 settimane fa) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Mercoledì 6 Novembre 2024 (3 settimane fa) • Edgar (US Regulatory)

Form 8-K - Current report
Mercoledì 6 Novembre 2024 (3 settimane fa) • Edgar (US Regulatory)

Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
Mercoledì 6 Novembre 2024 (3 settimane fa) • Business Wire

Form 144 - Report of proposed sale of securities
Venerdì 1 Novembre 2024 (4 settimane fa) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Venerdì 1 Novembre 2024 (4 settimane fa) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Giovedì 31 Ottobre 2024 (4 settimane fa) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Venerdì 25 Ottobre 2024 (1 mese fa) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Venerdì 25 Ottobre 2024 (1 mese fa) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Mercoledì 23 Ottobre 2024 (1 mese fa) • Edgar (US Regulatory)

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Mercoledì 23 Ottobre 2024 (1 mese fa) • Edgar (US Regulatory)

Più Janux Therapeutics Inc Articoli Notizie

Biomerieux 69 Marcy L Et... (PK)

Delayed Upgrade Clock

Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US ADVFN Korea